Stonvex
Stonvex
StonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for ATHE yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $4.25 | $4.33 | +2.00% | 0.0M |
| 05-19 | $4.13 | $4.27 | +3.39% | 0.0M |
| 05-20 | $4.31 | $4.27 | -0.93% | 0.0M |
| 05-21 | $4.27 | $4.18 | -2.11% | 0.0M |
| 05-22 | $4.24 | $4.14 | -2.36% | 0.0M |
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Fundamentals not available for ATHE yet.
We pull from FMP, Finnhub, and Polygon — common gaps are very recent IPOs that haven't filed their first 10-Q, pink-sheet OTC tickers, and foreign filers without US-listed depth. The Financials tab reads SEC EDGAR directly and may still have data here.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.